BBV154 - A novel adenovirus vectored, intranasal vaccine for COVID-19
Implementing Organization
Bharat Biotech, Hyderabad
Project Overview
DBT-BIRAC supported India's first Intranasal vaccine to prevent COVID-19 by Bharat Biotech private limited
Benefits
Immune responses at the site of infection (in the nasal mucosa) – essential for blocking both infection and transmission of COVID-19. The technology helps for pandemic preparedness
Bharat Biotech, Hyderabad
Accessibility Controls